Redirecting To American Academy of Dermatology AAD 2021 VMX
Sponsor-page-banner-GIRO

Welcome Video

Welcome AAD VMX 2021 

Let your virtual meeting experience begin! Stream 75+ educational sessions covering the full breadth of dermatology. Browse the agenda below and navigate to the session you’d like to watch, then simply expand the title and click “watch on-demand”. Once you’ve completed the session, you can claim CME under the “Resources” tab above. You can view sessions as many times as you’d like, even after claiming CME credit. All content, with the exception of the Live Demonstration sessions and select Industry Sessions, will be available on-demand through July 12.

Schedule

Print Schedule
All times are Pacific
Sort by Date
Sort by Track
   
9:00 AM - 10:00 AM (CT)
P000 - Keynote Speaker: Dani Shapiro

AAD gratefully acknowledges the support from Bristol Myers Squibb.

Dani Shapiro is the author of the best-selling memoir Inheritance. In the spring of 2016, through a genealogy website, Dani Shapiro received the stunning news that her father was not her biological father. Inheritance is a book about secrets — secrets we keep from one another in the name of love. It speaks to our extraordinary moment, when science and technology have outpaced not only medical ethics but also the capacities of the human heart to contend with what we discover.

*Please note this recording is only available until May 7th.

11:00 AM - 12:00 PM (CT)
AAD VMX Donor Kick-Off

AAD supporters are invited to this donor appreciation VMX launch event for a brief presentation hosted by AAD leadership, followed by small group discussions on timely topics with industry partners. This event will take place in Zoom and is accessible from the AAD Donor Appreciation booth (under the AAD Showcase dropdown menu).

On-Demand
Wellness Center

Take a quick 15-minute wellness break to relax and re-energize during AAD VMX. You can access four personal wellness videos that will help you refresh during the meeting from our Wellness Center.

 
On-Demand
AAD Talent Show

AAD’s got talent! Be sure to tune into the VMX Talent Show to see your skilled colleagues.

1:00 PM - 2:00 PM (CT)
Industry Sessions & Exhibits
1:25 PM - 1:55 PM (CT)
IS - Let’s Be RealisTYK: The Burden of Disease Management and the Role of TYK2 in Psoriasis - sponsored by Bristol Myers Squibb
N/A

Bristol Myers Squibb invites you to a virtual symposium where 3 leading experts in the field of dermatology will explore the unmet needs in the management of psoriasis and the role of TYK2 in the pathology of psoriasis and other autoimmune diseases. Despite the availability of treatment options, many patients with psoriasis are not treated or are undertreated.1,2 Shared decision-making and understanding patient preferences are crucial for treatment success.2,3 The TYK/JAK family members play a role in both immune and broader systemic cytokine signaling.4 For psoriasis, TYK/JAK-mediated signaling is involved in immune activation and recruitment to psoriatic lesion sites, and the perpetuation of lesions.4,5 Beyond psoriasis, these pathways play an important role in the pathology of psoriatic arthritis, inflammatory bowel diseases, and lupus, among other disorders.7-10 This demonstrates how a key pathogenic signaling axis may be shared across a range of different immune-mediated inflammatory diseases.6-10 References: 1. Armstrong AW et al. Dermatol Ther (Heidelb). 2017;7:97-109. 2. Lebwohl MG et al. Am J Clin Dermatol. 2016;17:87–97. 3. Alcusky M et al. Dermatol Ther (Heidelb). 2017;7:463–483. 4. Bannerjee S et al. Drugs. 2017;77:521-546. 5. Hawkes JE et al. J Allergy Clin Immunol. 2017;140:645-653.

1:25 PM - 1:55 PM (CT)
IS - Atopic Dermatitis Clinical Case Discussion - sponsored by Regeneron and Sanofi Genzyme
N/A

Come hear an expert discussion on the evaluation and management of a patient with uncontrolled moderate-to-severe atopic dermatitis and a treatment option for your appropriate patients.

2:00 PM - 3:00 PM (CT)
F016 - The Elusive CTCL: An Interactive Case-based CPC for Diagnosis and Management
N/A N/A N/A

4

The goal of the session is to highlight "elusive" and clinically overlapping presentations of CTCL and to engage the audience in discussions around how to effectively work up, diagnose and treat varying subtypes of CTCL.

  • Differentiate different morphologic subtypes of CTCL
  • Diagnose and stage CTCL more effectively
  • Recognize appropriate treatment modalities based on subtype of disease
On-Demand
Lymphomatoid Papulosis – Or is it?
N/A
On-Demand
CD 8+ Cutaneous T-Cell Lymphoma
N/A
On-Demand
The Elusive CTCL
On-Demand
A Patient with Localized Alopecia and Follicular Accentuation
On-Demand
Case Presentation
On-Demand
The Elusive CTCL: An Interactive Case-based CPC for Diagnosis and Management
N/A
2:00 PM - 3:00 PM (CT)
F022 - Documentation and Coding: Getting Paid and Passing Audits 2021
N/A N/A

Dermatologists often feel overwhelmed with constantly changing coding and documentation requirements as well as burdensome insurer and regulatory mandates. Insurers place hurdles to appropriate reimbursement for services and are reviewing medical records with increasing frequency. Worse yet, a dermatologist may be faced with a serious audit or recoupment demand. This session will provide dermatologists with an update of the latest coding and documentation guidelines; examine those practice and coding areas most at risk for review or audit; and outline a plan for responding to insurer medical audits.

  • Discuss the latest trends in insurer and Medicare audits and medical record reviews.
  • Describe the most recent documentation and medical record requirements including 2021 Evaluation and Management code updates
  • Identify available resources and develop an appropriate plan of action if targetted for insurer audit.
On-Demand
Modifier 25 - Insurer’s Favorite New Target
On-Demand
2021 Coding Changes - What you need to know
N/A
On-Demand
You’re Getting Audited! - What Do You Do Now?
N/A
2:00 PM - 3:00 PM (CT)
S007 - LGBTQ/SGM Health in Dermatology: Updates & Pearls in a Changing Landscape

5

This session aims to better enable dermatologists to provide medically appropriate, culturally sensitive, and culturally humble care to LGBTQ/SGM persons. Covering basic and advanced knowledge domains in LGBTQ/SGM healthcare, topics include skin cancer in sexual minority populations; dermatologic management of gender diverse individuals with a focus on acne, hair removal considerations, minimally invasive procedures, and the role of contraception and how to manage contraception as part of dermatology therapeutics in the gender diverse patient; and state and federal policy framework for contextualizing the impact of discrimination and its intersection with access to affirming care and health outcomes.

  • Summarize and discuss LGBTQ/SGM-related health disparities, including dermatology-related and overall health disparities, as well as general approaches to establishing a safe space for LGBTQ/SGM individuals and evidence-based practices when providing excellent dermatologic care for this population.
  • Describe public policy in the United States as it pertains to LGBTQ/SGM people at the state and federal levels through executive, legislative, and judiciary action and describe how such policy impacts the healthcare of LGBTQ/SGM patients at the intersection of social determinants of health.
  • Identify and discuss the importance of the inclusion of LGBTQ/SGM health topics in undergraduate, graduate, and continuing medical education, and review the role of workforce diversity in health professions, including dermatology, in affecting health outcomes and health disparities in LGBTQ/SGM patients.
On-Demand
HPV and LGBTQ/SGM Health
On-Demand
Acne in Gender Diverse Persons
On-Demand
Overview of SGM/LGBTQ Health Policy: State of the Landscape
On-Demand
Gender Affirming Procedures: Injectables
On-Demand
Contraception for transgender men and gender nonbinary individuals
On-Demand
Skin Cancer in SGM Persons
On-Demand
Minimally Invasive Procedures in Gender-Affirming Care: Fundamentals and Pearls
On-Demand
Hair Removal Considerations in Gender-Affirming Care
2:00 PM - 3:00 PM (CT)
S025 - Live Demonstration: Soft Tissue Augmentation and Neuromodulators – Simultaneous Cadaver Prosection and Live Patient Injections
N/A

3

Content for the Live Demonstration is Live only and will not be listed for On Demand viewed after the scheduled session time.

This session will include demonstration of newly FDA-approved tools to augment existing nonsurgical rejuvenation. Attendees will have the unique opportunity to see live patient assessment and treatments along-side demonstration of pertinent anatomy on a dissected cadaver - techniques have evolved to require injections at various tissue planes, therefore understanding anatomy is extremely important in order to avoid complications and maximize patient outcomes. Live patient demonstrations will include augmentation with dermal fillers, treatment of submental fullness, and optimal use of neuromodulators.

  • Recognize and identify facial and neck anatomy as it relates to the use of cosmetic injections.
  • Assess and avoid complications injecting at various face and neck locations and depths.
  • Develop a therapeutic rejuvenation plan utilizing a combination of nonsurgical treatments.
2:00 PM - 3:00 PM (CT)
U001 - Cutaneous Dysesthesias

Neurocutaneous dysesthesias can be a challenge to diagnose and treat. We look to the literature for an evidence-based three part talk on some difficult diseases in this field: 1) what's new in neurocutaneous dysesthesias, 2) vulvodynia pearls, and 3) an update in anogenital pruritus.

  • Detect diseases that fall under the category of cutaneous dyesthesias.
  • Prescribe appropriate medications to manage diseases that are of neurocutaneous origin.
  • Recognize comorbidities which may have higher prevalence in patients with neurocutaneous dysesthesias, such as idiopathic anogenial pruritus.
On-Demand
What's New in Neurocutaneous Dysesthesias
On-Demand
Vulvodynia for the Dermatologist
On-Demand
An Update in Anogenital Pruritus
3:30 PM - 4:30 PM (CT)
F010 - How can the Appropriate Use Criteria in Dermatopathology be utilized by the practicing dermatologist?
N/A

3

Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy, and physician decision-making. The American Society of Dermatopathology with input from the American Academy of Dermatology and the College of American Pathologists developed AUC for 12 tests used in dermatopathology. The recommendations of appropriateness will be reviewed with an emphasis of clinical scenarios that affect the practicing dermatologist.

  • Recognize what appropriate use criteria are and how they are developed.
  • Identify the ancillary studies for which appropriate use criteria have been developed in dermatopathology.
  • Examine how appropriate use criteria can be applied in clinical scenarios encountered in practice.
On-Demand
Why are AUC important in our future?
N/A
On-Demand
Appropriate Use Criteria in Dermatopathology Overview
On-Demand
Muir-Torre and HPV AUC
On-Demand
Melanocytic AUC
On-Demand
Lymphoproliferative AUC
3:30 PM - 4:30 PM (CT)
F026 - Integrative Dermatology: What is the Evidence?
N/A

2

This session explores different traditions and their approaches to dermatologic problems. From botanicals, ayurvedic approaches, herbs, and mind-body therapies, there is growing interest in these complementary therapies. Importantly, there also exists a body of evidence, and we will carefully review the extant literature.

  • Describe the evidence for integrative approaches in dermatology
  • Describe the potential pitfalls with integrative treatments and this approach
  • Outline some of the potential benefits of an integrative approach in dermatology
On-Demand
Integrative Approaches to Hair Disorders
On-Demand
Introduction to Integrative Dermatology
On-Demand
Integrative Approaches to Acne and Rosacea
N/A
On-Demand
Integrative Approaches to Atopic Dermatitis
3:30 PM - 4:30 PM (CT)
S001 - Complex Medical Dermatology
N/A

5

The skin is frequently reflective of internal disease. This session will update the attendees with new aspects of such diseases and prepare them for developing effective, efficient plans for evaluation of such patients. In addition, attendees will be provided with a therapeutic scheme for cost-effective management. Off-label uses of medications will occur, but we will use the best level of evidence available for the basis of the therapeutic discussions.

  • Diagnose patients with complex medical/dermatologic problems, including, but not limited to pyoderma gangrenosum, pemphigus, sarcoidosis, alpha-gal syndrome, and lupus erythematosus
  • Develop an effective evaluation of patients with complex medical/dermatologic problems
  • Develop a therapeutic ladder for effective management of Complex medical dermatologic conditions
On-Demand
Pyoderma gangrenosum - What's new in diagnosing and managing patients
N/A
On-Demand
Sarcoidosis - evaluation and management, what's new?
On-Demand
Cutaneous lupus erythematosus - what's new in its management
On-Demand
Approach to a patient with a complex medical/dermatological condition
On-Demand
Alpha-Gal syndrome - why and what Dermatologists need to know
On-Demand
Pemphigus - Diagnosis, evaluation and management
On-Demand
Does the use of systemic corticosteroids, antimalarials or beta-blockers have an impact on patients with psoriasis
3:30 PM - 4:30 PM (CT)
S008 - Acne and Rosacea Symposium
N/A N/A N/A N/A

7

We will review the state of the art in our current understanding of the pathogenesis of acne and rosacea and compare the added benefit of new treatment options, including pipeline drugs.

  • Examine the current understanding of the pathophysiology of acne and rosacea
  • Assess the treatment benefits of newly approved treatment options in acne and rosacea
  • Analyze the new mechanisms of action in the pipeline for treatment options
On-Demand
Are Acne and Rosacea Diseases if Dysbiosis?
On-Demand
Acne Scars: Practical Tips from the "Motor City"
N/A
On-Demand
Update on Acne Pathogenesis: 2021
On-Demand
Update on Isotretinoin
On-Demand
What's New in topical treatment of acne
N/A
On-Demand
Update on oral antibiotic therapy
On-Demand
Hormonal therapy for acne: What you need to know
N/A
On-Demand
Rosacea: What's New and What's Coming
On-Demand
Update on treatment of Dyspigmentation
N/A
3:30 PM - 4:30 PM (CT)
U009 - Managing Advanced Non-Melanoma Skin Cancer - Choosing the Right Pathway for the Right Patient
N/A

This session is intended to provide the attendee with an overview of the expanding systemic, non-surgical options for advanced non-melanoma skin cancer, for which there is no standardized management approach. While surgery is a viable option for many patients, it also may carry the risk of cosmetic and functional incapacity. Available treatments, both systemic and topical will be discussed with a focus on the data and an eye toward future developments. Attendees should be more comfortable discussing options with their patients and colleagues for the management of advanced nonmelanoma skin cancer.

  • Assess a patient suffering from advanced non-melanoma skin cancer and determine whether the patient is a good surgical candidate or if an alternative management plan should be considered.
  • Analyze available data on primary systemic and adjuvant treatment options for non-melanoma skin cancer and describe the involvement of the multidisciplinary team in the management plan.
  • Distinguish among the available options for advanced non-melanoma skin cancer and develop a treatment plan that is tailored to an individual patient.
On-Demand
Managing Advanced Non-Melanoma Skin Cancer - Current and Upcoming Therapy
N/A
On-Demand
Managing Advanced Non-Melanoma Skin Cancer - Choosing the Right Pathway for the Right Patient
4:30 PM - 5:30 PM (CT)
Industry Sessions & Exhibits
4:35 PM - 5:05 PM (CT)
IS - Perspectives in generalized pustular psoriasis: from pathophysiology to practice - sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
N/A

Generalized pustular psoriasis (GPP) is genetically and clinically distinct from psoriasis vulgaris, yet may still be incorrectly considered the same disease. Recent findings have uncovered greater genetic information with respect to differences in generalized pustular psoriasis and psoriasis vulgaris. Uncontrolled activation of the IL-36 pathway can drive inflammatory pustular skin diseases. Targeting this pathway may prove a feasible approach to treating generalized pustular psoriasis.

4:35 PM - 5:05 PM (CT)
IS - BENCH-TO-BEDSIDE SUCCESS FOR ATOPIC DERMATITIS: FOLLOWING IN THE FOOTSTEPS OF PSORIASIS? - sponsored by LEO Pharma

Incredible therapeutic advances in psoriasis have occurred in the last 20 years, most of which stemmed directly from scientific discoveries in the immunopathogenesis of this disease. Similar scientific work along with subsequent translational studies are now rapidly occurring in atopic dermatitis. Here, Dr. Andrew Blauvelt will review key recent scientific findings on atopic dermatitis, discuss how this work is being translated into clinical studies with new targeted therapies, and review important differences in psoriasis drug development versus atopic dermatitis drug development, highlighting the challenges that we still face with treatments for atopic dermatitis.

5:30 PM - 6:30 PM (CT)
S004 - What's New in the Dermatology Journals
N/A N/A N/A

Editors of our key journals will discuss advances in medical, surgical and pediatric dermatology

  • Treat inflammatory disease more effectively
  • Treat neoplastic disease more effectively
  • Describe the risks of medical therapy
On-Demand
What New in BJD
On-Demand
What's New in JAAD
N/A
On-Demand
What's New in JAMA Derm
N/A
On-Demand
Editor's Pick of the Year - JEADV
N/A
5:30 PM - 6:30 PM (CT)
S028 - COVID-19 Symposium
N/A N/A N/A N/A

7

In this session we will hear from experts in COVID-19 dermatology. This symposium will serve as an overview of key topics in COVID-19, ranging from COVID skin manifestations, COVID-19 and skin of color, COVID-19 vaccines, COVID-19 and biologics, and affects of COVID on dermatology training and practice.

  • Describe and diagnose the spectrum of COVID-19 related dermatoses in children and adults, and across different skin types.
  • Assess how the COVID-19 pandemic has affected dermatologic training and care provision.
  • Prepare for, and respond to, skin reactions to the COVID-19 vaccines.
On-Demand
Introduction, COVID-19 registries
On-Demand
COVID-19 Dermatologic Manifestations - morphology
N/A
On-Demand
COVID-19 and pediatric dermatology
N/A
On-Demand
COVID-19 immunology
On-Demand
COVID-19 and skin of color
N/A
On-Demand
COVID-19 Managing a Derm practice during a pandemic
N/A
On-Demand
COVID-19 and Derm Training
On-Demand
COVID-19 Vaccines
5:30 PM - 6:30 PM (CT)
U008 - Off-label use of biologics and new medications

During the session, off-label use of biologic and other specialty drugs will be reviewed. The aim is to help the practioner optimize the delivery of appropriate treatments for patients. Medications to be discussed include TNF-alpha inhibitors, anti-IL17 antibodies, anti-IL23 biologics, dupilumab, apremilast, and JAK inhibitors.

  • Discuss the data behind use of apremilast for patients with lichen planus
  • Summarize the data for use of TNF-alpha inhibitors for the treatment of granulomatous conditions such as granuloma annulare and sarcoidosis.
  • Describe the emerging data on the use of dupilumab for bullous pemphigoid
On-Demand
Off-Label Use of TNF-Alpha Inhibitors Ustekinumab, and JAK inhibitors
On-Demand
Off-label Biologics
6:00 PM - 9:00 PM (CT)
F006 - Innovate for Impact: Solving Clinical Problems through Creativity and Collaboration in Dermatology
N/A

3

This interactive forum will cultivate creativity and collaboration among learners. The forum features an overview of the innovation process through a series of dynamic didactic talks on how to identify clinical problems and unmet needs, how to brainstorm and prototype potential solutions, how to identify stakeholders, how to to collaborate with researchers and how to pitch solutions for further development and commercialization. The didactic talks will be punctuated with small, interactive, breakout sessions where learners can practice innovation in real-time and apply it to a clinical problem that is personally meaningful to them.

  • Discuss how to identify unmet clinical needs for patients and populations in diverse settings.
  • Describe the process of innovation and design thinking (identify the problem, brainstorm solutions, build a team of stakeholders, prototype, iterate with feedback, and pitch).
  • Apply the innovation process to each learner’s identified clinical problem and evaluate the potential impact, scalability, and sustainability of the innovation.
On-Demand
Invent: Prototype, Pilot, Repeat
On-Demand
Implementation: Scalability. Sustainability.Strategy
On-Demand
Innovate for Impact: Solving Clinical Problems through Creativity and Collaboration in Dermatology
7:00 PM - 8:00 PM (CT)
F009 - What’s that? Syndrome Update
N/A N/A

Using case examples, this session will review key clinical points and updates relevant to genetic skin disorders in a dermatology clinic.

  • Recognize cutaneous signs of inherited disease more accurately.
  • Identify indications for genetics referral and testing.
  • Access local resources for genetic disorders.
On-Demand
Syndromes with Disordered Connective Tissue
N/A